

Duplicate
- 892
Duplicate
Duplicate
Duplicate
Duplicate

Duplicate
- Duplicate
Duplicate

/LegalA-F/Bjornholm Maria/Legal/HYBRIDON/47508.423/1449b.wpf

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

7

of

2


Attorney Docket Number	475-08-423
------------------------	------------

[illegible][illegible]

06-19-00

Burden-Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



App. for use through 10/31/99. OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/283,431
		Filing Date	April 1, 1999
		First Named Inventor	Agrawal, et al
		Group Art Unit	1635
		Examiner Name	S. Latimer
		Attorney Docket Number	475.08.423
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAL	B1	GHOSH M K et al, Phosphorothioate phosphodiester oligonucleotide copolymers: assessment for antisense application. Anti-Cancer Drug Design, 8 (1), Feb. 1993, pp. 15-32.	
KAL	B2	PATIL S V et al, Syntheses and Properties of Oligothymidylate Analogs Containing... Bioorganic & Medicinal Chemistry Letters, 4 (22), 1994, pp. 2663-2666.	
KAL	B3	YASWEN P et al, Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Research and Development, 3 (1), Spring 1993, pp. 67-77.	
KAL	B4	ZHAO Q et al, Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation. Biochem. Pharmacol., 51 (2), Jan. 26, 1996, pp. 173-182.	
KAL	B5	ZHOU W et al, Mixed-backbone oligonucleotides as second-generation antisense agents with reduced... Bioorganic & Medicinal Chem. Let., 8 (2), Nov. 17, 1998, pp. 3269-3274.	

Examiner Signature	<i>Karen A. Lacourciere</i>	Date Considered	06-19-00
--------------------	-----------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+